Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $78.23 and traded as high as $90.80. Kiniksa Pharmaceuticals International shares last traded at $89.20, with a volume of 2,320,220 shares changing hands.

Trending Headlines about Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Results surpassed estimates: Third-quarter EPS was $0.56, up from $0.23 a year earlier and above consensus estimates of approximately $0.32–$0.37. Revenue reached $285.97 million, exceeding the roughly $260.66 million analyst forecast. Kiniksa Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: ARCALYST continues to drive growth: The cardiovascular drug generated approximately $286 million in third-quarter net product revenue, representing about 58% year-over-year growth. Penetration among patients with multiple recurrences reached 23%, indicating continued room for expansion. Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Guidance was raised: Kiniksa now expects 2026 ARCALYST net product revenue of $1.045 billion to $1.050 billion, reinforcing expectations for sustained commercial momentum. Kiniksa Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Pipeline milestone: KPL-387 pivotal Phase 3 data is expected in the second half of 2027. The program could broaden Kiniksa’s portfolio, but the catalyst remains relatively distant and carries clinical-development risk. Kiniksa Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Reported short interest was zero shares as of October 26, offering no indication of meaningful short-selling pressure, although the figure may reflect reporting or data limitations.

Analyst Ratings Changes

Several analysts have issued reports on the company. The Goldman Sachs Group boosted their price target on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Wells Fargo & Company initiated coverage on Kiniksa Pharmaceuticals International in a research note on Wednesday, September 30th. They issued an “overweight” rating and a $87.00 price objective on the stock. Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and an average price target of $93.14.

Kiniksa Pharmaceuticals International Trading Up 22.2%

The business has a 50-day moving average price of $78.23 and a 200 day moving average price of $59.23.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The business had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently bought and sold shares of the business. Headlands Technologies LLC purchased a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $1,161,000. Inspire Investing LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $1,698,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $631,000. Handelsbanken Fonder AB purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $1,343,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Kiniksa Pharmaceuticals International by 56.7% in the 1st quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company’s stock worth $3,050,000 after purchasing an additional 22,917 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.